Peripheral BDNF/TrkB protein expression is decreased in Parkinson's disease but not in Essential tremor. (May 2019)

• Record Type: Journal Article
• Authors: Huang, Yixian; Huang, Caili; Yun, Wenwei
• Is Part Of: Journal of clinical neuroscience. Volume 63(2019)
• Page Start: 176
• Page End: 181
• Publication Date: 2019-05
• Subjects: Parkinson's disease -- Essential tremor -- Brain-derived neurotrophic factor -- TrkB; Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2019.01.017
• Languages: English
• ISSNs: 0967-5868

Abstract

Highlights: BDNF and phosphorylated TrkB levels were significantly decreased in the PD. BDNF levels were positively correlated with disease duration, UPDRS and H-Y in PD patients. Phosphorylated TrkB levels were positively correlated with disease duration, UPDRS and H-Y in PD patients. Increased level of BDNF and phosphorylated TrkB at advanced stages may due to L-DOPA medication. Abstract: BDNF-to-TrkB signaling pathways plays an important role in the long-term maintenance of the nigrostriatal system and that its deficiency may contribute to the onset and progression of Parkinson's disease (PD). To our knowledge this is the first study to investigate the expression of the brain-derived neurotrophic factor (BDNF) and phosphorylation status of TrkB in peripheral blood lymphocytes of 28 PD and 28 Essential tremor (ET) patients and 28 healthy controls using western blot analysis. Compared with controls, no significant difference of BDNF and total and phosphorylated TrkB levels were observed in ET, whereas BDNF and phosphorylated TrkB levels were significantly decreased in the PD groups (p < 0.001). Interestingly, BDNF and phosphorylated TrkB levels were positively correlated with disease duration, UPDRS score, Hoehn-Yahr staging, as well as L-DOPA medication in PD patients. These results suggest that the decreased peripheral alteration of BDNF/TrkB levels found in patients with PD is directly related to the dopaminergic neurons neurodegeneration and that decreased expression of BDNF/TrkB may lead to the development of innovative biomarkers of PD, whereas the increased level of BDNF and phosphorylated TrkB at advanced stages may due to L-DOPA medication.